Cresols
Apexbio Technology LLC Ansamitocin P-3 66547-09-9 10mg
Ansamitocin P-3 (CAS 66547-09-9) is a small-molecule inhibitor targeting tubulin It is designed to disrupt microtubule assembly by potently inhibiting tubulin polymerization thereby affecting cellular processes reliant on microtubule dynamics Ansamitocin P-3 exerts its biological activity primarily through inhibition of tubulin polymerization In cell-based studies Ansamitocin P-3 demonstrates cytotoxicity with IC50 values of approximately 4 10 g/ml in human lung carcinoma A-549 and colon carcinoma HT-29 cells and 2 10 g/ml in breast carcinoma MCF-7 cells Additionally it inhibits ciliary regeneration in Tetrahymena cells at concentrations around 1 M Based on these pharmacological properties Ansamitocin P-3 holds research potential in oncology particularly in studies of microtubule dynamics anticancer drug mechanisms and ciliogenesis
Apexbio Technology LLC Ansamitocin P-3 66547-09-9 5mg
Ansamitocin P-3 (CAS 66547-09-9) is a small-molecule inhibitor targeting tubulin It is designed to disrupt microtubule assembly by potently inhibiting tubulin polymerization thereby affecting cellular processes reliant on microtubule dynamics Ansamitocin P-3 exerts its biological activity primarily through inhibition of tubulin polymerization In cell-based studies Ansamitocin P-3 demonstrates cytotoxicity with IC50 values of approximately 4 10 g/ml in human lung carcinoma A-549 and colon carcinoma HT-29 cells and 2 10 g/ml in breast carcinoma MCF-7 cells Additionally it inhibits ciliary regeneration in Tetrahymena cells at concentrations around 1 M Based on these pharmacological properties Ansamitocin P-3 holds research potential in oncology particularly in studies of microtubule dynamics anticancer drug mechanisms and ciliogenesis
Apexbio Technology LLC Ansamitocin P-3 66547-09-9 25mg
Ansamitocin P-3 (CAS 66547-09-9) is a small-molecule inhibitor targeting tubulin It is designed to disrupt microtubule assembly by potently inhibiting tubulin polymerization thereby affecting cellular processes reliant on microtubule dynamics Ansamitocin P-3 exerts its biological activity primarily through inhibition of tubulin polymerization In cell-based studies Ansamitocin P-3 demonstrates cytotoxicity with IC50 values of approximately 4 10 g/ml in human lung carcinoma A-549 and colon carcinoma HT-29 cells and 2 10 g/ml in breast carcinoma MCF-7 cells Additionally it inhibits ciliary regeneration in Tetrahymena cells at concentrations around 1 M Based on these pharmacological properties Ansamitocin P-3 holds research potential in oncology particularly in studies of microtubule dynamics anticancer drug mechanisms and ciliogenesis
Apexbio Technology LLC Ansamitocin P-3 66547-09-9 50mg
Ansamitocin P-3 (CAS 66547-09-9) is a small-molecule inhibitor targeting tubulin It is designed to disrupt microtubule assembly by potently inhibiting tubulin polymerization thereby affecting cellular processes reliant on microtubule dynamics Ansamitocin P-3 exerts its biological activity primarily through inhibition of tubulin polymerization In cell-based studies Ansamitocin P-3 demonstrates cytotoxicity with IC50 values of approximately 4 10 g/ml in human lung carcinoma A-549 and colon carcinoma HT-29 cells and 2 10 g/ml in breast carcinoma MCF-7 cells Additionally it inhibits ciliary regeneration in Tetrahymena cells at concentrations around 1 M Based on these pharmacological properties Ansamitocin P-3 holds research potential in oncology particularly in studies of microtubule dynamics anticancer drug mechanisms and ciliogenesis
Apexbio Technology LLC Ansamitocin P-3 66547-09-9 10mM (in 1mL DMSO)
Ansamitocin P-3 (CAS 66547-09-9) is a small-molecule inhibitor targeting tubulin It is designed to disrupt microtubule assembly by potently inhibiting tubulin polymerization thereby affecting cellular processes reliant on microtubule dynamics Ansamitocin P-3 exerts its biological activity primarily through inhibition of tubulin polymerization In cell-based studies Ansamitocin P-3 demonstrates cytotoxicity with IC50 values of approximately 4 10 g/ml in human lung carcinoma A-549 and colon carcinoma HT-29 cells and 2 10 g/ml in breast carcinoma MCF-7 cells Additionally it inhibits ciliary regeneration in Tetrahymena cells at concentrations around 1 M Based on these pharmacological properties Ansamitocin P-3 holds research potential in oncology particularly in studies of microtubule dynamics anticancer drug mechanisms and ciliogenesis